ERBB2 and breast carcinoma: In the treatment of HER2-positive advanced breast cancer: The EMILIA clinical trial (NCT00829166) compared the efficacy of T-DM1 with lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer who had previously received trastuzumab and taxanes (Verma et al., 2012).